Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis

Company Overview

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for metabolic and liver diseases. The company’s lead product candidate, Aramchol® (arachidyl amido cholanoic acid), is a proprietary fatty acid–bile acid conjugate designed to target nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH). Galmed’s research aims to address key metabolic pathways implicated in liver fat accumulation and inflammation.

Aramchol is currently being evaluated in late-stage clinical trials, with a focus on demonstrating its potential to reduce liver fat content, improve markers of liver inflammation, and halt or reverse fibrotic progression. Preclinical studies have shown that Aramchol modulates both lipid metabolism and fibrogenesis, making it a dual-action candidate in the NASH treatment landscape. The company’s pipeline also includes earlier-stage assets targeting other metabolic diseases, leveraging its platform technology for lipid modulation.

Galmed Pharmaceuticals maintains strategic partnerships and licensing agreements to expand the global reach of Aramchol. The company has granted regional rights to various pharmaceutical partners for development and commercialization in markets such as Europe, Canada, and select Asian countries. Headquartered in Tel Aviv, Israel, Galmed operates R&D facilities there and engages with clinical research organizations across North America and Europe to conduct its pivotal trials.

Founded in 2000, Galmed has been led by an experienced management team with deep expertise in biotechnology and drug development. The company’s Executive Chairman, Dr. Yair Schwarz, co-founded Galmed and has guided its strategic direction, while William Mahoney, Chief Financial Officer, oversees financial planning and regulatory affairs. Together with a board of directors comprising industry veterans, Galmed seeks to advance its clinical programs and position Aramchol as a novel therapeutic option for patients suffering from NASH and related metabolic disorders.

Key Stats

• Today's Range: $1.87 to $2.05
• 50-Day Range: $1.19 to $2.18
• 52-Week Range: $1.15 to $23.80
• Volume: 317,224 shs
• Average Volume: 1.34 million shs
• Market Capitalization: $3.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Galmed Pharmaceuticals Stock Analysis - MarketRank™

Galmed Pharmaceuticals scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Galmed Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Galmed Pharmaceuticals is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Galmed Pharmaceuticals is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Galmed Pharmaceuticals has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.17% of the float of Galmed Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Galmed Pharmaceuticals has recently increased by 36.47%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Galmed Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Galmed Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.17% of the float of Galmed Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Galmed Pharmaceuticals has recently increased by 36.47%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Galmed Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Galmed Pharmaceuticals this week, compared to 0 articles on an average week.

MarketBeat Follows

Only 1 people have added Galmed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.80% of the stock of Galmed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

76.14% of the stock of Galmed Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GLMD Stock Analysis - Frequently Asked Questions

How have GLMD shares performed this year?

Galmed Pharmaceuticals' stock was trading at $3.19 at the beginning of the year. Since then, GLMD shares have decreased by 39.5% and is now trading at $1.93.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) issued its earnings results on Thursday, May, 22nd. The biopharmaceutical company reported ($0.62) EPS for the quarter.

When did Galmed Pharmaceuticals' stock split?

Galmed Pharmaceuticals shares reverse split on Monday, May 15th 2023.The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Galmed Pharmaceuticals investors own include Viking Therapeutics (VKTX), OPKO Health (OPK), SCYNEXIS (SCYX), Bristol Myers Squibb (BMY), Plug Power (PLUG), Applied Genetic Technologies (AGTC) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 5/22/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLMD
• CIK: 1595353
• Web: www.galmedpharma.com
• Phone: (723) 693-8448
• Fax: 972-3693-8447
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($16.66)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.52 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -32.21%
• Return on Assets: -28.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.02
• Quick Ratio: 9.02

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.87 per share
• Price / Book: 0.20

Miscellaneous

• Outstanding Shares: 1,650,000
• Free Float: 1,327,000
• Market Cap: $3.18 million
• Optionable: Not Optionable
• Beta: 0.60